Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAHLVE: Bevacizumab vs Aflibercept in Wet AMD
NCT04101877Phase 2Active, not recruiting
- Sponsor
- Region Västra Götaland
- Start
- Sep 2020
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Region Västra Götaland. Started Sep 2020; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04101877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101877.